Combination of EUTOS Score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy

导出原文传递

翻译打印收藏纠错

作者： Tiribelli, Mario ^[1] ; Binotto, Gianni ^[2] ; Calistri, Elisabetta ^[3] ; Maino, Elena ^[4] ; Scaffidi, Luigi ^[5] ; Medeot, Marta ; Nabergoj, Mitja ; Ambrosetti, Achille ; Semenzato, Gianpietro ; Fanin, Renato ; Bonifacio, Massimiliano

作者单位： Azienda Osped Univ, Dept Expt & Clin Sci, Div Hematol & BMT, Udine, Italy ^[1] Padua Sch Med, Dept Med Hematol & Clin Immunol, Padua, Italy ^[2] Ca Foncello Hosp, Div Hematol, Treviso, Italy ^[3] Angelo Hosp, Div Hematol, Venice, Italy ^[4] Univ Verona, Dept Med, I-37100 Verona, Italy ^[5]

发布时间 2015-09-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

American Journal of Hematology

2015年90卷7期

E135-E137页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Combination of EUTOS Score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy

American Journal of Hematology

相似文献

American Journal of Hematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Combination of EUTOS Score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy

American Journal of Hematology

相似文献

American Journal of Hematology

相关期刊

检索历史清除